Significant tumor growth attenuation could be achieved with only partial reduction in FOXP3 mRNA in preclinical studies (17), indicating that AZD8701 may provide clinical antitumor activity at levels of FOXP3 reduction that do not impact self-tolerance. Here, FOXP3 is linked to neoplasm.